Status:
COMPLETED
Effect of Kunamin in SARS-CoV-2 RT-PCR Positive Covid-19 Patients
Lead Sponsor:
RAAS Nutritionals, LLC
Collaborating Sponsors:
Kayseri City Hospital
Conditions:
COVID-19 Respiratory Infection
FLU
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The primary objective of this study is to determine the safety and efficacy profile of the food supplement (KUNAMIN®) containing grape juice, seed, stem, and bark given to patients treated with the es...
Detailed Description
We conducted a medical observation from December 2019 when there were no cases and no deaths in America, and just the revelation of this new disease in China. There is still no cure for COVID-19, a ve...
Eligibility Criteria
Inclusion
- Uncomplicated, mild or moderate pneumonia according to the T.R. Ministry of Health COVID-19 guidelines,
- Adult patients diagnosed with COVID-19
- Being between the age of 18 and 65
- Adult patients diagnosed with COVID-19 by PCR and who have COVID-19 symptoms in CT scan
- Patients who are positive for 2019-nCOVRNA in the test performed on samples taken from the nasopharyngeal area
- Respiratory rate less than 30 / minute
- SpO2 level above 90% in room air
- Finding signs of pneumonia on chest x-ray or tomography
- Having symptoms of COVID19
- Having the skills to understand and approve the informed consent form
- Patients with mild to moderate pneumonia findings according to the above criteria and decided to be treated only in hospital,
Exclusion
- Those who are allergic to grape juice and seed extract and / or other drugs and / or excipients of the products included in the standard treatment regimen,
- Pregnant or breastfeeding women
- Those who are not suitable for oral medication
- Patients who have comorbidity and using medication because of their chronic illness
- SpO2 level below 90% in room air
- Those who have diffuse pneumonia findings in chest tomography and radiography
- Patients who are being isolated and treated at home
Key Trial Info
Start Date :
May 29 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 2 2021
Estimated Enrollment :
71 Patients enrolled
Trial Details
Trial ID
NCT05417997
Start Date
May 29 2021
End Date
December 2 2021
Last Update
June 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kayseri City Hospital
Kayseri, Kayseri, Turkey (Türkiye), 38080